132 related articles for article (PubMed ID: 30706190)
1. Factors influencing the use of extended adjuvant endocrine therapy.
Kadakia KC; Kidwell KM; Barton DL; Schott AF; Hayes DF; Griggs JJ; Henry NL
Breast Cancer Res Treat; 2019 May; 175(1):181-189. PubMed ID: 30706190
[TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
3. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
4. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Fallowfield LJ; Leaity SK; Howell A; Benson S; Cella D
Breast Cancer Res Treat; 1999 May; 55(2):189-99. PubMed ID: 10481946
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
6. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
7. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
[TBL] [Abstract][Full Text] [Related]
8. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
Hamelinck VC; Bastiaannet E; Pieterse AH; de Glas NA; Portielje JE; Merkus JW; den Hoed ID; van de Velde CJ; Liefers GJ; Stiggelbout AM
Clin Breast Cancer; 2016 Oct; 16(5):379-388. PubMed ID: 27212474
[TBL] [Abstract][Full Text] [Related]
14. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
15. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ
Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Hershman DL; Kushi LH; Hillyer GC; Coromilas E; Buono D; Lamerato L; Bovbjerg DH; Mandelblatt JS; Tsai WY; Zhong X; Jacobson JS; Wright JD; Neugut AI
Breast Cancer Res Treat; 2016 May; 157(1):133-43. PubMed ID: 27086286
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Dixon JM; Renshaw L; Langridge C; Young OE; McHugh M; Williams L; Murray J; Macaskill EJ; McCaig F; Dixon OM; Fallowfield LJ
Breast Cancer Res Treat; 2011 Feb; 125(3):741-9. PubMed ID: 20821047
[TBL] [Abstract][Full Text] [Related]
19. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
